Overview

The Genetics Company Inc. is a high-throughput company focusing on in vivo functional genomics. It uses proprietary assays and genetics in well-characterized model organisms, such as the fruit fly and the mouse, to convert DNA sequence and genetic information into validated molecular targets and pharmacologically active small compounds and proteins.

The Genetics Company was founded in July 1998 as a spin-off from the University of Zurich and the Swiss Institute for Experimental Cancer Research in Epalinges (Lausanne). The Swiss company operates through two sites, Zurich and Epalinges, and is headquartered in Zurich.

Technology platforms include InvoTarget for genetic screens; InvoScreen for chemical genetics; INTROx for high-throughput expression cloning of human morphogenetic proteins; and INVOx for conditional in vivo validation of cancer targets and morphogenetic proteins. Its InvoBase Database is comprised of in vivo functional data.

The Genetics Company has initiated and is conducting in-house and collaborative research in seven different programs to develop therapeutic approaches for humans and livestock in areas including cancer, endocrine disorders, inflammation (innate immunity), tissue regeneration and anti-parasites.

Partners

Collaboration to identify precursors for drug leads to treat colon cancer: Discovery Technologies Ltd.

Identification of novel anti-parasitics: Intervet GmbH, a subsidiary of Akzo Nobel.